{"transactions":[{"id":683969,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":22381,"kind":"person","name":"Zawitz David","position":1,"cik":"0002046750","reported_name":"Zawitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-08-18T21:00:15.000Z","date":"2026-08-17","kind":"purchase","planned":false,"acquired":true,"shares":6000,"price":4.98,"value":29880.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.90 to $5.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":27000,"source":{"system":"sec-edgar","filing":"0002046750-26-000004","document":"form4-08182026_050804.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2046750/000204675026000004/form4-08182026_050804.xml","form_type":"4"}},{"id":683966,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":22377,"kind":"person","name":"Rieger Jayson","position":1,"cik":"0002043558","reported_name":"Rieger Jayson","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2026-08-18T21:00:14.000Z","date":"2026-08-17","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":4.91,"value":24550.0,"ownership":{"direct":true},"balance_after":207593,"source":{"system":"sec-edgar","filing":"0002043558-26-000005","document":"form4-08182026_050802.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2043558/000204355826000005/form4-08182026_050802.xml","form_type":"4"}},{"id":683965,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":22377,"kind":"person","name":"Rieger Jayson","position":1,"cik":"0002043558","reported_name":"Rieger Jayson","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2026-08-18T21:00:14.000Z","date":"2026-08-14","kind":"purchase","planned":false,"acquired":true,"shares":20000,"price":5.06,"value":101200.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.04 to $5.088 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":202593,"source":{"system":"sec-edgar","filing":"0002043558-26-000005","document":"form4-08182026_050802.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2043558/000204355826000005/form4-08182026_050802.xml","form_type":"4"}},{"id":683513,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":22223,"kind":"person","name":"Rosenberg Noah L.","position":1,"cik":"0001579649","reported_name":"Rosenberg Noah L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Common Stock","published_at":"2026-08-18T21:00:14.000Z","date":"2026-08-18","kind":"purchase","planned":false,"acquired":true,"shares":2030,"price":4.92,"value":9987.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.90 to $4.95 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":8587,"source":{"system":"sec-edgar","filing":"0001579649-26-000005","document":"form4-08182026_050809.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000157964926000005/form4-08182026_050809.xml","form_type":"4"}},{"id":683512,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":22223,"kind":"person","name":"Rosenberg Noah L.","position":1,"cik":"0001579649","reported_name":"Rosenberg Noah L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Common Stock","published_at":"2026-08-18T21:00:14.000Z","date":"2026-08-17","kind":"purchase","planned":false,"acquired":true,"shares":4200,"price":4.91,"value":20622.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.90 to $4.95 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":6557,"source":{"system":"sec-edgar","filing":"0001579649-26-000005","document":"form4-08182026_050809.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000157964926000005/form4-08182026_050809.xml","form_type":"4"}},{"id":683511,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":22222,"kind":"person","name":"Kirby John J.","position":1,"cik":"0001556327","reported_name":"Kirby John J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO"}}],"security":"Common Stock","published_at":"2026-08-18T21:00:13.000Z","date":"2026-08-18","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":4.93,"value":24650.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.85 to $4.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":23962,"source":{"system":"sec-edgar","filing":"0001556327-26-000003","document":"form4-08182026_050806.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000155632726000003/form4-08182026_050806.xml","form_type":"4"}},{"id":744603,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":40055,"kind":"person","name":"Eichenfield Lawrence","position":1,"cik":"0001814892","reported_name":"Eichenfield Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-09T20:15:30.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 5, 2026 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director through the applicable vesting date."}],"balance_after":16000,"derivative":{"exercise_price":6.04,"expiration_date":"2036-06-04","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001814892-26-000002","document":"form4-06092026_040606.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000181489226000002/form4-06092026_040606.xml","form_type":"4"}},{"id":744746,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":35681,"kind":"person","name":"Nguyen Diem","position":1,"cik":"0001814338","reported_name":"Nguyen Diem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-09T20:15:28.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 5, 2026 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director through the applicable vesting date."}],"balance_after":16000,"derivative":{"exercise_price":6.04,"expiration_date":"2036-06-04","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001814338-26-000002","document":"form4-06092026_040603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814338/000181433826000002/form4-06092026_040603.xml","form_type":"4"}},{"id":744602,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":40054,"kind":"person","name":"PRYGOCKI MARK A SR","position":1,"cik":"0001257544","reported_name":"PRYGOCKI MARK A SR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-09T20:15:27.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 5, 2026 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director through the applicable vesting date."}],"balance_after":16000,"derivative":{"exercise_price":6.04,"expiration_date":"2036-06-04","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001257544-26-000002","document":"form4-06092026_040601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000125754426000002/form4-06092026_040601.xml","form_type":"4"}},{"id":744604,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":22223,"kind":"person","name":"Rosenberg Noah L.","position":1,"cik":"0001579649","reported_name":"Rosenberg Noah L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-06-09T20:15:19.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":233840,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option grant was approved by a committee of the Issuer's board of directors on December 23, 2025, subject to shareholder approval of an amendment to the Issuer's 2018 Equity Incentive Plan under which the option was granted. The Issuer's shareholders approved the amendment on June 5, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"50% of the total shares subject to the option shall vest on the date that the closing sales price per share of the Issuer's Common Stock as reported on The Nasdaq Capital Market equals at least $15.00, and 50% of the total shares subject to the option shall vest on the date that the closing sales price per share of the Issuer's Common Stock as reported on The Nasdaq Capital Market equals at least $25.00, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":233840,"derivative":{"exercise_price":8.21,"expiration_date":"2035-12-23","underlying":"Common Stock","underlying_shares":233840},"source":{"system":"sec-edgar","filing":"0001579649-26-000002","document":"form4-06092026_040614.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000157964926000002/form4-06092026_040614.xml","form_type":"4"}},{"id":745002,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":22381,"kind":"person","name":"Zawitz David","position":1,"cik":"0002046750","reported_name":"Zawitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-06-09T20:15:16.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":171340,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option grant was approved by a committee of the Issuer's board of directors on December 23, 2025, subject to shareholder approval of an amendment to the Issuer's 2018 Equity Incentive Plan under which the option was granted. The Issuer's shareholders approved the amendment on June 5, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"50% of the total shares subject to the option shall vest on the date that the closing sales price per share of the Issuer's Common Stock as reported on The Nasdaq Capital Market equals at least $15.00, and 50% of the total shares subject to the option shall vest on the date that the closing sales price per share of the Issuer's Common Stock as reported on The Nasdaq Capital Market equals at least $25.00, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":171340,"derivative":{"exercise_price":8.21,"expiration_date":"2035-12-23","underlying":"Common Stock","underlying_shares":171340},"source":{"system":"sec-edgar","filing":"0002046750-26-000002","document":"form4-06092026_040612.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2046750/000204675026000002/form4-06092026_040612.xml","form_type":"4"}},{"id":744999,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":22377,"kind":"person","name":"Rieger Jayson","position":1,"cik":"0002043558","reported_name":"Rieger Jayson","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-06-09T20:15:14.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":512269,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option grant was approved by a committee of the Issuer's board of directors on December 23, 2025, subject to shareholder approval of an amendment to the Issuer's 2018 Equity Incentive Plan under which the option was granted. The Issuer's shareholders approved the amendment on June 5, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"50% of the total shares subject to the option shall vest on the date that the closing sales price per share of the Issuer's Common Stock as reported on The Nasdaq Capital Market equals at least $15.00, and 50% of the total shares subject to the option shall vest on the date that the closing sales price per share of the Issuer's Common Stock as reported on The Nasdaq Capital Market equals at least $25.00, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":512269,"derivative":{"exercise_price":8.21,"expiration_date":"2035-12-23","underlying":"Common Stock","underlying_shares":512269},"source":{"system":"sec-edgar","filing":"0002043558-26-000002","document":"form4-06092026_040610.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2043558/000204355826000002/form4-06092026_040610.xml","form_type":"4"}},{"id":744601,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":40053,"kind":"person","name":"Corcoran Gavin","position":1,"cik":"0001745995","reported_name":"Corcoran Gavin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-09T20:15:12.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 5, 2026 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director through the applicable vesting date."}],"balance_after":16000,"derivative":{"exercise_price":6.04,"expiration_date":"2036-06-04","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001745995-26-000002","document":"form4-06092026_040608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000174599526000002/form4-06092026_040608.xml","form_type":"4"}},{"id":957198,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":22222,"kind":"person","name":"Kirby John J.","position":1,"cik":"0001556327","reported_name":"Kirby John J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO"}}],"security":"Common Stock","published_at":"2025-12-30T13:00:05.000Z","date":"2025-12-23","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a fully vested restricted stock unit award."}],"balance_after":18962,"source":{"system":"sec-edgar","filing":"0001556327-25-000006","document":"form4-12302025_081201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000155632725000006/form4-12302025_081201.xml","form_type":"4"}},{"id":988688,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":22223,"kind":"person","name":"Rosenberg Noah L.","position":1,"cik":"0001579649","reported_name":"Rosenberg Noah L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Series C Warrant (right to buy)","published_at":"2025-11-26T00:00:16.000Z","date":"2025-11-25","kind":"purchase","planned":false,"acquired":true,"shares":589,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported securities are included within 2,357 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately exercisable."}],"balance_after":589,"derivative":{"exercise_price":6.315,"expiration_date":"2030-11-25","underlying":"Common Stock","underlying_shares":589},"source":{"system":"sec-edgar","filing":"0001579649-25-000004","document":"form4-11252025_071113.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000157964925000004/form4-11252025_071113.xml","form_type":"4"}},{"id":988687,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":22223,"kind":"person","name":"Rosenberg Noah L.","position":1,"cik":"0001579649","reported_name":"Rosenberg Noah L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Common Stock","published_at":"2025-11-26T00:00:16.000Z","date":"2025-11-25","kind":"purchase","planned":false,"acquired":true,"shares":2357,"price":4.2425,"value":9999.5725,"ownership":{"direct":true},"balance_after":2357,"source":{"system":"sec-edgar","filing":"0001579649-25-000004","document":"form4-11252025_071113.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000157964925000004/form4-11252025_071113.xml","form_type":"4"}},{"id":988686,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":22222,"kind":"person","name":"Kirby John J.","position":1,"cik":"0001556327","reported_name":"Kirby John J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO"}}],"security":"Series C Warrant (right to buy)","published_at":"2025-11-26T00:00:14.000Z","date":"2025-11-25","kind":"purchase","planned":false,"acquired":true,"shares":884,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported securities are included within 3,536 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Immediately exercisable."}],"balance_after":884,"derivative":{"exercise_price":6.315,"expiration_date":"2030-11-25","underlying":"Common Stock","underlying_shares":884},"source":{"system":"sec-edgar","filing":"0001556327-25-000004","document":"form4-11252025_071111.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000155632725000004/form4-11252025_071111.xml","form_type":"4"}},{"id":988685,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":22222,"kind":"person","name":"Kirby John J.","position":1,"cik":"0001556327","reported_name":"Kirby John J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO"}}],"security":"Common Stock","published_at":"2025-11-26T00:00:14.000Z","date":"2025-11-25","kind":"purchase","planned":false,"acquired":true,"shares":3536,"price":4.2425,"value":15001.48,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split."}],"balance_after":8962,"source":{"system":"sec-edgar","filing":"0001556327-25-000004","document":"form4-11252025_071111.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000155632725000004/form4-11252025_071111.xml","form_type":"4"}},{"id":988963,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":22381,"kind":"person","name":"Zawitz David","position":1,"cik":"0002046750","reported_name":"Zawitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Series C Warrant (right to buy)","published_at":"2025-11-26T00:00:13.000Z","date":"2025-11-25","kind":"purchase","planned":false,"acquired":true,"shares":2500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported securities are included within 10,000 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Immediately exercisable."}],"balance_after":2500,"derivative":{"exercise_price":6.315,"expiration_date":"2030-11-25","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0002046750-25-000004","document":"form4-11252025_071109.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2046750/000204675025000004/form4-11252025_071109.xml","form_type":"4"}},{"id":988962,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":22381,"kind":"person","name":"Zawitz David","position":1,"cik":"0002046750","reported_name":"Zawitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-11-26T00:00:13.000Z","date":"2025-11-25","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":4.2425,"value":42425.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split."}],"balance_after":21000,"source":{"system":"sec-edgar","filing":"0002046750-25-000004","document":"form4-11252025_071109.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2046750/000204675025000004/form4-11252025_071109.xml","form_type":"4"}},{"id":988960,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":22377,"kind":"person","name":"Rieger Jayson","position":1,"cik":"0002043558","reported_name":"Rieger Jayson","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Series C Warrant (right to buy)","published_at":"2025-11-26T00:00:11.000Z","date":"2025-11-25","kind":"purchase","planned":false,"acquired":true,"shares":23577,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported securities are included within 94,311 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":23577,"derivative":{"exercise_price":6.315,"expiration_date":"2030-11-25","underlying":"Common Stock","underlying_shares":23577},"source":{"system":"sec-edgar","filing":"0002043558-25-000003","document":"form4-11252025_071107.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2043558/000204355825000003/form4-11252025_071107.xml","form_type":"4"}},{"id":988959,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":22377,"kind":"person","name":"Rieger Jayson","position":1,"cik":"0002043558","reported_name":"Rieger Jayson","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2025-11-26T00:00:11.000Z","date":"2025-11-25","kind":"purchase","planned":false,"acquired":true,"shares":94311,"price":4.2425,"value":400114.4175,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split."}],"balance_after":182593,"source":{"system":"sec-edgar","filing":"0002043558-25-000003","document":"form4-11252025_071107.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2043558/000204355825000003/form4-11252025_071107.xml","form_type":"4"}},{"id":988672,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Warrant (right to buy)","published_at":"2025-11-26T00:00:09.000Z","date":"2025-11-25","kind":"purchase","planned":false,"acquired":true,"shares":687690,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The reported securities are included within 2,750,762 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 49.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Immediately exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by BKB Growth Investments, LLC (\"BKB\"). The Reporting Person is a co-manager of the manager of BKB and has shared voting and investment power with respect to the shares held by BKB."}],"balance_after":687690,"derivative":{"exercise_price":6.315,"expiration_date":"2030-11-25","underlying":"Common Stock","underlying_shares":687690},"source":{"system":"sec-edgar","filing":"0001494695-25-000004","document":"form4-11252025_071105.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000149469525000004/form4-11252025_071105.xml","form_type":"4"}},{"id":988671,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Warrant (right to buy)","published_at":"2025-11-26T00:00:09.000Z","date":"2025-11-25","kind":"purchase","planned":false,"acquired":true,"shares":343845,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The reported securities are included within 1,375,380 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 49.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Immediately exercisable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held by Mr. Manning jointly with his spouse."}],"balance_after":343845,"derivative":{"exercise_price":6.315,"expiration_date":"2030-11-25","underlying":"Common Stock","underlying_shares":343845},"source":{"system":"sec-edgar","filing":"0001494695-25-000004","document":"form4-11252025_071105.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000149469525000004/form4-11252025_071105.xml","form_type":"4"}},{"id":988670,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-26T00:00:09.000Z","date":"2025-11-25","kind":"purchase","planned":false,"acquired":true,"shares":2750762,"price":4.2425,"value":11670107.785,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by BKB Growth Investments, LLC (\"BKB\"). The Reporting Person is a co-manager of the manager of BKB and has shared voting and investment power with respect to the shares held by BKB."}],"balance_after":3348372,"source":{"system":"sec-edgar","filing":"0001494695-25-000004","document":"form4-11252025_071105.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000149469525000004/form4-11252025_071105.xml","form_type":"4"}},{"id":988669,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-26T00:00:09.000Z","date":"2025-11-25","kind":"purchase","planned":false,"acquired":true,"shares":1375380,"price":4.2425,"value":5835049.65,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held by Mr. Manning jointly with his spouse."}],"balance_after":3958189,"source":{"system":"sec-edgar","filing":"0001494695-25-000004","document":"form4-11252025_071105.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000149469525000004/form4-11252025_071105.xml","form_type":"4"}},{"id":1117869,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":40053,"kind":"person","name":"Corcoran Gavin","position":1,"cik":"0001745995","reported_name":"Corcoran Gavin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-09T20:45:21.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 5, 2025 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director through the applicable vesting date."}],"balance_after":20000,"derivative":{"exercise_price":0.58,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001415889-25-016290","document":"form4-06092025_040607.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588925016290/form4-06092025_040607.xml","form_type":"4"}},{"id":1118064,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":35681,"kind":"person","name":"Nguyen Diem","position":1,"cik":"0001814338","reported_name":"Nguyen Diem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-09T20:45:16.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 5, 2025 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director through the applicable vesting date."}],"balance_after":20000,"derivative":{"exercise_price":0.58,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001415889-25-016288","document":"form4-06092025_040603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814338/000141588925016288/form4-06092025_040603.xml","form_type":"4"}},{"id":1117868,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":40055,"kind":"person","name":"Eichenfield Lawrence","position":1,"cik":"0001814892","reported_name":"Eichenfield Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-09T20:45:11.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 5, 2025 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director through the applicable vesting date."}],"balance_after":20000,"derivative":{"exercise_price":0.58,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001415889-25-016287","document":"form4-06092025_040601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588925016287/form4-06092025_040601.xml","form_type":"4"}},{"id":1117867,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":40054,"kind":"person","name":"PRYGOCKI MARK A SR","position":1,"cik":"0001257544","reported_name":"PRYGOCKI MARK A SR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-09T20:45:10.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 5, 2025 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director through the applicable vesting date."}],"balance_after":20000,"derivative":{"exercise_price":0.58,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001415889-25-016289","document":"form4-06092025_040605.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588925016289/form4-06092025_040605.xml","form_type":"4"}},{"id":1183412,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":40053,"kind":"person","name":"Corcoran Gavin","position":1,"cik":"0001745995","reported_name":"Corcoran Gavin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-02T20:32:51.000Z","date":"2025-03-31","kind":"grant","planned":false,"acquired":true,"shares":17502,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3rd of the total shares subject to the option shall vest on March 31, 2026, and 1/36th of the total shares subject to the option shall vest in 24 monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":17502,"derivative":{"exercise_price":0.44,"expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":17502},"source":{"system":"sec-edgar","filing":"0001415889-25-009654","document":"form4-04022025_080448.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588925009654/form4-04022025_080448.xml","form_type":"4"}},{"id":1190859,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":22223,"kind":"person","name":"Rosenberg Noah L.","position":1,"cik":"0001579649","reported_name":"Rosenberg Noah L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-03-26T11:10:45.000Z","date":"2025-03-24","kind":"grant","planned":false,"acquired":true,"shares":325000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/8th of the total shares subject to the option shall vest on September 24, 2025, and 1/48th of the total shares subject to the option shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":325000,"derivative":{"exercise_price":0.52,"expiration_date":"2035-03-24","underlying":"Common Stock","underlying_shares":325000},"source":{"system":"sec-edgar","filing":"0001415889-25-008999","document":"form4-03262025_110341.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588925008999/form4-03262025_110341.xml","form_type":"4"}},{"id":1200777,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":22377,"kind":"person","name":"Rieger Jayson","position":1,"cik":"0002043558","reported_name":"Rieger Jayson","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-03-18T22:45:07.000Z","date":"2025-03-14","kind":"grant","planned":false,"acquired":true,"shares":850000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/8th of the total shares subject to the option shall vest on September 14, 2025, and 1/48th of the total shares subject to the option shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":850000,"derivative":{"exercise_price":0.89,"expiration_date":"2035-03-14","underlying":"Common Stock","underlying_shares":850000},"source":{"system":"sec-edgar","filing":"0001415889-25-008506","document":"form4-03182025_060303.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2043558/000141588925008506/form4-03182025_060303.xml","form_type":"4"}},{"id":1200107,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":81825,"kind":"person","name":"Hayes Christopher G.","position":1,"cik":"0001805359","reported_name":"Hayes Christopher G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF LEGAL OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-03-18T18:45:05.000Z","date":"2025-03-14","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"50% of the total shares subject to the option shall vest on each of March 14, 2026 and March 14, 2027, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":250000,"derivative":{"exercise_price":0.89,"expiration_date":"2035-03-14","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001415889-25-008505","document":"form4-03182025_060301.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805359/000141588925008505/form4-03182025_060301.xml","form_type":"4"}},{"id":1200106,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":81825,"kind":"person","name":"Hayes Christopher G.","position":1,"cik":"0001805359","reported_name":"Hayes Christopher G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2025-03-18T18:45:05.000Z","date":"2025-03-17","kind":"sale","planned":false,"acquired":false,"shares":4315,"price":0.65,"value":2804.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary sale by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6378 to $0.6605 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":176458,"source":{"system":"sec-edgar","filing":"0001415889-25-008505","document":"form4-03182025_060301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805359/000141588925008505/form4-03182025_060301.xml","form_type":"4"}},{"id":1280323,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":83526,"kind":"person","name":"Goldenberg Gary","position":1,"cik":"0001741938","reported_name":"Goldenberg Gary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-02-06T21:15:17.000Z","date":"2023-08-24","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit (\"RSU\") awards with performance based vesting, which were originally granted in March 2023. The RSUs vested 50% upon the first commercial sale of VP-102 on August 24, 2023, and the remaining 50% vested on August 24, 2024, the one year anniversary of the first sale."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of RSUs awarded in the initial Form 4 was unintentionally misreported, as only the number of shares that vested on August 24, 2023 were reported as opposed to the full size of the award. This amendment corrects the number RSUs awarded and the number of securities beneficially owned after the reported transaction."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The number of RSUs awarded in the initial Form 4 was unintentionally misreported, as only the number of shares that vested on August 24, 2023 were reported as opposed to the full size of the award. This amendment corrects the number RSUs awarded and the number of securities beneficially owned after the reported transaction."}],"balance_after":120110,"source":{"system":"sec-edgar","filing":"0001415889-25-003234","document":"form4a-02062025_040211.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588925003234/form4a-02062025_040211.xml","form_type":"4/A","original_submission_date":"2023-08-28"}},{"id":1280431,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":29785,"kind":"person","name":"Kohler Terry","position":1,"cik":"0001872285","reported_name":"Kohler Terry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-06T21:15:13.000Z","date":"2023-08-24","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit (\"RSU\") awards with performance based vesting, which were originally granted in March 2023. The RSUs vested 50% upon the first commercial sale of VP-102 on August 24, 2023, and the remaining 50% vested on August 24, 2024, the one year anniversary of the first sale."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of RSUs awarded in the initial Form 4 was unintentionally misreported, as only the number of shares that vested on August 24, 2023 were reported as opposed to the full size of the award. This amendment corrects the number RSUs awarded and the number of securities beneficially owned after the reported transaction."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The number of RSUs awarded in the initial Form 4 was unintentionally misreported, as only the number of shares that vested on August 24, 2023 were reported as opposed to the full size of the award. This amendment corrects the number RSUs awarded and the number of securities beneficially owned after the reported transaction."}],"balance_after":125000,"source":{"system":"sec-edgar","filing":"0001415889-25-003233","document":"form4a-02062025_040208.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1872285/000141588925003233/form4a-02062025_040208.xml","form_type":"4/A","original_submission_date":"2023-08-28"}},{"id":1280322,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":83525,"kind":"person","name":"White Ted","position":1,"cik":"0001741964","reported_name":"White Ted","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2025-02-06T21:15:07.000Z","date":"2023-08-24","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit (\"RSU\") awards with performance based vesting, which were originally granted in March 2023. The RSUs vested 50% upon the first commercial sale of VP-102 on August 24, 2023, and the remaining 50% vested on August 24, 2024, the one year anniversary of the first sale."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of RSUs awarded in the initial Form 4 was unintentionally misreported, as only the number of shares that vested on August 24, 2023 were reported as opposed to the full size of the award. This amendment corrects the number RSUs awarded and the number of securities beneficially owned after the reported transaction."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The number of RSUs awarded in the initial Form 4 was unintentionally misreported, as only the number of shares that vested on August 24, 2023 were reported as opposed to the full size of the award. This amendment corrects the number RSUs awarded and the number of securities beneficially owned after the reported transaction."}],"balance_after":278789,"source":{"system":"sec-edgar","filing":"0001415889-25-003231","document":"form4a-02062025_040204.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588925003231/form4a-02062025_040204.xml","form_type":"4/A","original_submission_date":"2023-08-28"}},{"id":1280321,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":83524,"kind":"person","name":"Bonaccorso Joe","position":1,"cik":"0001741973","reported_name":"Bonaccorso Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF COMMERCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-06T21:15:05.000Z","date":"2023-08-24","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit (\"RSU\") awards with performance based vesting, which were originally granted in March 2023. The RSUs vested 50% upon the first commercial sale of VP-102 on August 24, 2023, and the remaining 50% vested on August 24, 2024, the one year anniversary of the first sale."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of RSUs awarded in the initial Form 4 was unintentionally misreported, as only the number of shares that vested on August 24, 2023 were reported as opposed to the full size of the award. This amendment corrects the number RSUs awarded and the number of securities beneficially owned after the reported transaction."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The number of RSUs awarded in the initial Form 4 was unintentionally misreported, as only the number of shares that vested on August 24, 2023 were reported as opposed to the full size of the award. This amendment corrects the number RSUs awarded and the number of securities beneficially owned after the reported transaction."}],"balance_after":187738,"source":{"system":"sec-edgar","filing":"0001415889-25-003230","document":"form4a-02062025_040201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588925003230/form4a-02062025_040201.xml","form_type":"4/A","original_submission_date":"2023-08-28"}},{"id":1280360,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":81825,"kind":"person","name":"Hayes Christopher G.","position":1,"cik":"0001805359","reported_name":"Hayes Christopher G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-06T16:15:10.000Z","date":"2023-08-24","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit (\"RSU\") awards with performance based vesting, which were originally granted in March 2023. The RSUs vested 50% upon the first commercial sale of VP-102 on August 24, 2023, and the remaining 50% vested on August 24, 2024, the one year anniversary of the first sale."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of RSUs awarded in the initial Form 4 was unintentionally misreported, as only the number of shares that vested on August 24, 2023 were reported as opposed to the full size of the award. This amendment corrects the number RSUs awarded and the number of securities beneficially owned after the reported transaction."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The number of RSUs awarded in the initial Form 4 was unintentionally misreported, as only the number of shares that vested on August 24, 2023 were reported as opposed to the full size of the award. This amendment corrects the number RSUs awarded and the number of securities beneficially owned after the reported transaction."}],"balance_after":231925,"source":{"system":"sec-edgar","filing":"0001415889-25-003232","document":"form4a-02062025_040206.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805359/000141588925003232/form4a-02062025_040206.xml","form_type":"4/A","original_submission_date":"2023-08-28"}},{"id":1339314,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":22381,"kind":"person","name":"Zawitz David","position":1,"cik":"0002046750","reported_name":"Zawitz David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-12-09T22:18:25.000Z","date":"2024-12-09","kind":"grant","planned":false,"acquired":true,"shares":950000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/8th of the total shares subject to the option shall vest on June 9, 2025, and 1/48th of the total shares subject to the option shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":950000,"derivative":{"exercise_price":0.95,"expiration_date":"2034-12-09","underlying":"Common Stock","underlying_shares":950000},"source":{"system":"sec-edgar","filing":"0001415889-24-028674","document":"form4-12092024_101222.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2046750/000141588924028674/form4-12092024_101222.xml","form_type":"4"}},{"id":1351277,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":22377,"kind":"person","name":"Rieger Jayson","position":1,"cik":"0002043558","reported_name":"Rieger Jayson","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Series B Warrants (right to buy)","published_at":"2024-11-26T21:15:13.000Z","date":"2024-11-22","kind":"purchase","planned":false,"acquired":true,"shares":140449,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within 280,898 investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise."}],"balance_after":140449,"derivative":{"exercise_price":1.335,"exercise_date":"2024-11-22","expiration_date":"2029-11-22","underlying":"Common Stock","underlying_shares":140449},"source":{"system":"sec-edgar","filing":"0001415889-24-027711","document":"form4-11262024_041106.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/2043558/000141588924027711/form4-11262024_041106.xml","form_type":"4"}},{"id":1351276,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":22377,"kind":"person","name":"Rieger Jayson","position":1,"cik":"0002043558","reported_name":"Rieger Jayson","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Series A Warrants (right to buy)","published_at":"2024-11-26T21:15:13.000Z","date":"2024-11-22","kind":"purchase","planned":false,"acquired":true,"shares":140449,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within 280,898 investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise."}],"balance_after":140449,"derivative":{"exercise_price":1.068,"exercise_date":"2024-11-22","expiration_date":"2025-11-22","underlying":"Common Stock","underlying_shares":140449},"source":{"system":"sec-edgar","filing":"0001415889-24-027711","document":"form4-11262024_041106.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/2043558/000141588924027711/form4-11262024_041106.xml","form_type":"4"}},{"id":1351275,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":22377,"kind":"person","name":"Rieger Jayson","position":1,"cik":"0002043558","reported_name":"Rieger Jayson","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2024-11-26T21:15:13.000Z","date":"2024-11-26","kind":"gift","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":882826,"source":{"system":"sec-edgar","filing":"0001415889-24-027711","document":"form4-11262024_041106.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2043558/000141588924027711/form4-11262024_041106.xml","form_type":"4"}},{"id":1351274,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":22377,"kind":"person","name":"Rieger Jayson","position":1,"cik":"0002043558","reported_name":"Rieger Jayson","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2024-11-26T21:15:13.000Z","date":"2024-11-22","kind":"purchase","planned":false,"acquired":true,"shares":280898,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within 280,898 investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise."}],"balance_after":832826,"source":{"system":"sec-edgar","filing":"0001415889-24-027711","document":"form4-11262024_041106.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2043558/000141588924027711/form4-11262024_041106.xml","form_type":"4"}},{"id":1350930,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort John A III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Warrants (right to buy)","published_at":"2024-11-26T21:15:08.000Z","date":"2024-11-22","kind":"purchase","planned":false,"acquired":true,"shares":561797,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within 1,123,595  investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise."}],"balance_after":561797,"derivative":{"exercise_price":1.335,"exercise_date":"2024-11-22","expiration_date":"2029-11-22","underlying":"Common Stock","underlying_shares":561797},"source":{"system":"sec-edgar","filing":"0001415889-24-027710","document":"form4-11262024_041104.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924027710/form4-11262024_041104.xml","form_type":"4"}},{"id":1350929,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort John A III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Warrants (right to buy)","published_at":"2024-11-26T21:15:08.000Z","date":"2024-11-22","kind":"purchase","planned":false,"acquired":true,"shares":561797,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within 1,123,595  investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise."}],"balance_after":561797,"derivative":{"exercise_price":1.068,"exercise_date":"2024-11-22","expiration_date":"2025-11-22","underlying":"Common Stock","underlying_shares":561797},"source":{"system":"sec-edgar","filing":"0001415889-24-027710","document":"form4-11262024_041104.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924027710/form4-11262024_041104.xml","form_type":"4"}},{"id":1350928,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort John A III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-26T21:15:08.000Z","date":"2024-11-26","kind":"gift","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1873800,"source":{"system":"sec-edgar","filing":"0001415889-24-027710","document":"form4-11262024_041104.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924027710/form4-11262024_041104.xml","form_type":"4"}},{"id":1350927,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":40808,"kind":"person","name":"Stalfort John A III","position":1,"cik":"0001709418","reported_name":"Stalfort John A III","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-26T21:15:08.000Z","date":"2024-11-22","kind":"purchase","planned":false,"acquired":true,"shares":1123595,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within 1,123,595  investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise."}],"balance_after":1823800,"source":{"system":"sec-edgar","filing":"0001415889-24-027710","document":"form4-11262024_041104.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924027710/form4-11262024_041104.xml","form_type":"4"}},{"id":1350926,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Warrants (right to buy)","published_at":"2024-11-26T21:15:07.000Z","date":"2024-11-22","kind":"purchase","planned":false,"acquired":true,"shares":2247191,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported securities are included within 4,494,382 investment units purchased by BKB Growth Investments, LLC (\"BKB\") for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, one Series A warrant and one Series B warrant, each to purchase up to 2,247,191 shares of common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by BKB. The Reporting Person is a co-manager of the manager of BKB and has shared voting and investment power with respect to the shares held by BKB."}],"balance_after":2247191,"derivative":{"exercise_price":1.335,"exercise_date":"2024-11-22","expiration_date":"2029-11-22","underlying":"Common Stock","underlying_shares":2247191},"source":{"system":"sec-edgar","filing":"0001415889-24-027709","document":"form4-11262024_041101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924027709/form4-11262024_041101.xml","form_type":"4"}},{"id":1350925,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrants (right to buy)","published_at":"2024-11-26T21:15:07.000Z","date":"2024-11-22","kind":"purchase","planned":false,"acquired":true,"shares":2247191,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported securities are included within 4,494,382 investment units purchased by BKB Growth Investments, LLC (\"BKB\") for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, one Series A warrant and one Series B warrant, each to purchase up to 2,247,191 shares of common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by BKB. The Reporting Person is a co-manager of the manager of BKB and has shared voting and investment power with respect to the shares held by BKB."}],"balance_after":2247191,"derivative":{"exercise_price":1.068,"exercise_date":"2024-11-22","expiration_date":"2025-11-22","underlying":"Common Stock","underlying_shares":2247191},"source":{"system":"sec-edgar","filing":"0001415889-24-027709","document":"form4-11262024_041101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924027709/form4-11262024_041101.xml","form_type":"4"}},{"id":1350924,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Warrants (right to buy)","published_at":"2024-11-26T21:15:07.000Z","date":"2024-11-22","kind":"purchase","planned":false,"acquired":true,"shares":9213483,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within 18,426,966 investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock,a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 49.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held by Mr. Manning jointly with his spouse."}],"balance_after":9213483,"derivative":{"exercise_price":1.335,"exercise_date":"2024-11-22","expiration_date":"2029-11-22","underlying":"Common Stock","underlying_shares":9213483},"source":{"system":"sec-edgar","filing":"0001415889-24-027709","document":"form4-11262024_041101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924027709/form4-11262024_041101.xml","form_type":"4"}},{"id":1350923,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrants (right to buy)","published_at":"2024-11-26T21:15:07.000Z","date":"2024-11-22","kind":"purchase","planned":false,"acquired":true,"shares":9213483,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within 18,426,966 investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock,a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 49.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held by Mr. Manning jointly with his spouse."}],"balance_after":9213483,"derivative":{"exercise_price":1.068,"exercise_date":"2024-11-22","expiration_date":"2025-11-22","underlying":"Common Stock","underlying_shares":9213483},"source":{"system":"sec-edgar","filing":"0001415889-24-027709","document":"form4-11262024_041101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924027709/form4-11262024_041101.xml","form_type":"4"}},{"id":1350922,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-11-26T21:15:07.000Z","date":"2024-11-26","kind":"gift","planned":false,"acquired":false,"shares":450000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held by Mr. Manning jointly with his spouse."}],"balance_after":25828094,"source":{"system":"sec-edgar","filing":"0001415889-24-027709","document":"form4-11262024_041101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924027709/form4-11262024_041101.xml","form_type":"4"}},{"id":1350921,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-11-26T21:15:07.000Z","date":"2024-11-22","kind":"purchase","planned":false,"acquired":true,"shares":4494382,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported securities are included within 4,494,382 investment units purchased by BKB Growth Investments, LLC (\"BKB\") for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, one Series A warrant and one Series B warrant, each to purchase up to 2,247,191 shares of common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held directly by BKB. The Reporting Person is a co-manager of the manager of BKB and has shared voting and investment power with respect to the shares held by BKB."}],"balance_after":5976101,"source":{"system":"sec-edgar","filing":"0001415889-24-027709","document":"form4-11262024_041101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924027709/form4-11262024_041101.xml","form_type":"4"}},{"id":1350920,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-11-26T21:15:07.000Z","date":"2024-11-22","kind":"purchase","planned":false,"acquired":true,"shares":18426966,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within 18,426,966 investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock,a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 49.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held by Mr. Manning jointly with his spouse."}],"balance_after":26278094,"source":{"system":"sec-edgar","filing":"0001415889-24-027709","document":"form4-11262024_041101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924027709/form4-11262024_041101.xml","form_type":"4"}},{"id":1374194,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":22222,"kind":"person","name":"Kirby John J.","position":1,"cik":"0001556327","reported_name":"Kirby John J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO"}}],"security":"Common Stock","published_at":"2024-11-07T02:04:32.000Z","date":"2024-11-06","kind":"grant","planned":false,"acquired":true,"shares":54267,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs shall vest vest in full on May 4, 2025, subject to the Reporting Person's continuous service through such date."}],"balance_after":54267,"source":{"system":"sec-edgar","filing":"0001415889-24-026290","document":"form4-11072024_021129.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924026290/form4-11072024_021129.xml","form_type":"4"}},{"id":1374404,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":22377,"kind":"person","name":"Rieger Jayson","position":1,"cik":"0002043558","reported_name":"Rieger Jayson","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-11-07T02:02:43.000Z","date":"2024-11-06","kind":"grant","planned":false,"acquired":true,"shares":2000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/8th of the total shares subject to the option shall vest on May 5, 2025, and 1/48th of the total shares subject to the option shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":2000000,"derivative":{"exercise_price":0.7463,"expiration_date":"2034-11-06","underlying":"Common Stock","underlying_shares":2000000},"source":{"system":"sec-edgar","filing":"0001415889-24-026286","document":"form4-11072024_021140.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2043558/000141588924026286/form4-11072024_021140.xml","form_type":"4"}},{"id":1387594,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":81825,"kind":"person","name":"Hayes Christopher G.","position":1,"cik":"0001805359","reported_name":"Hayes Christopher G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF LEGAL OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-10-11T16:15:07.000Z","date":"2024-10-09","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"50% of the total shares subject to the option shall vest on each of April 9, 2025 and October 9, 2025, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":50000,"derivative":{"exercise_price":1.28,"expiration_date":"2034-10-09","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001415889-24-025026","document":"form4-10112024_041004.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805359/000141588924025026/form4-10112024_041004.xml","form_type":"4"}},{"id":1400884,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-23T20:15:04.000Z","date":"2024-09-19","kind":"gift","planned":false,"acquired":true,"shares":891870.42,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon termination of a Grantor Retained Annuity Trust, 2,675,611.25 shares were transferred to trusts for the benefit of the Reporting Person's immediate family members on September 19, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held in separate trusts for the benefit of the Reporting Person's immediate family members. The Reporting Person's spouse is trustee of each trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."}],"balance_after":891870.42,"source":{"system":"sec-edgar","filing":"0001415889-24-023835","document":"form4-09232024_040901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924023835/form4-09232024_040901.xml","form_type":"4"}},{"id":1400883,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-23T20:15:04.000Z","date":"2024-09-19","kind":"gift","planned":false,"acquired":true,"shares":891870.42,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon termination of a Grantor Retained Annuity Trust, 2,675,611.25 shares were transferred to trusts for the benefit of the Reporting Person's immediate family members on September 19, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held in separate trusts for the benefit of the Reporting Person's immediate family members. The Reporting Person's spouse is trustee of each trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."}],"balance_after":891870.42,"source":{"system":"sec-edgar","filing":"0001415889-24-023835","document":"form4-09232024_040901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924023835/form4-09232024_040901.xml","form_type":"4"}},{"id":1400882,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-23T20:15:04.000Z","date":"2024-09-19","kind":"gift","planned":false,"acquired":true,"shares":891870.41,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon termination of a Grantor Retained Annuity Trust, 2,675,611.25 shares were transferred to trusts for the benefit of the Reporting Person's immediate family members on September 19, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held in separate trusts for the benefit of the Reporting Person's immediate family members. The Reporting Person's spouse is trustee of each trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."}],"balance_after":891870.41,"source":{"system":"sec-edgar","filing":"0001415889-24-023835","document":"form4-09232024_040901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924023835/form4-09232024_040901.xml","form_type":"4"}},{"id":1400881,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":33957,"kind":"person","name":"Manning Paul B","position":1,"cik":"0001494695","reported_name":"Manning Paul B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-23T20:15:04.000Z","date":"2024-09-19","kind":"gift","planned":false,"acquired":false,"shares":2675611.25,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By GRAT"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon termination of a Grantor Retained Annuity Trust, 2,675,611.25 shares were transferred to trusts for the benefit of the Reporting Person's immediate family members on September 19, 2024."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-24-023835","document":"form4-09232024_040901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924023835/form4-09232024_040901.xml","form_type":"4"}},{"id":1420859,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":83526,"kind":"person","name":"Goldenberg Gary","position":1,"cik":"0001741938","reported_name":"Goldenberg Gary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-08-28T20:15:11.000Z","date":"2024-08-27","kind":"sale","planned":false,"acquired":false,"shares":3601,"price":2.46,"value":8858.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary sale by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.40 to $2.53 inclusive."}],"balance_after":94261,"source":{"system":"sec-edgar","filing":"0001415889-24-022426","document":"form4-08282024_040807.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924022426/form4-08282024_040807.xml","form_type":"4"}},{"id":1420858,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":83526,"kind":"person","name":"Goldenberg Gary","position":1,"cik":"0001741938","reported_name":"Goldenberg Gary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-08-28T20:15:11.000Z","date":"2024-08-26","kind":"sale","planned":false,"acquired":false,"shares":9888,"price":2.66,"value":26302.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary sale by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.53 to $2.83 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3)."}],"balance_after":97862,"source":{"system":"sec-edgar","filing":"0001415889-24-022426","document":"form4-08282024_040807.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924022426/form4-08282024_040807.xml","form_type":"4"}},{"id":1420857,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":83524,"kind":"person","name":"Bonaccorso Joe","position":1,"cik":"0001741973","reported_name":"Bonaccorso Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF COMMERCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-08-28T20:15:10.000Z","date":"2024-08-27","kind":"sale","planned":false,"acquired":false,"shares":8993,"price":2.46,"value":22122.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary sale by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.40 to $2.53 inclusive."}],"balance_after":73114,"source":{"system":"sec-edgar","filing":"0001415889-24-022425","document":"form4-08282024_040805.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924022425/form4-08282024_040805.xml","form_type":"4"}},{"id":1420856,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":83524,"kind":"person","name":"Bonaccorso Joe","position":1,"cik":"0001741973","reported_name":"Bonaccorso Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF COMMERCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-08-28T20:15:10.000Z","date":"2024-08-26","kind":"sale","planned":false,"acquired":false,"shares":24709,"price":2.66,"value":65725.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary sale by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.53 to $2.83 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3)."}],"balance_after":82107,"source":{"system":"sec-edgar","filing":"0001415889-24-022425","document":"form4-08282024_040805.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924022425/form4-08282024_040805.xml","form_type":"4"}},{"id":1421010,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":29785,"kind":"person","name":"Kohler Terry","position":1,"cik":"0001872285","reported_name":"Kohler Terry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-08-28T20:15:08.000Z","date":"2024-08-27","kind":"sale","planned":false,"acquired":false,"shares":7899,"price":2.46,"value":19431.54,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary sale by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.40 to $2.53 inclusive."}],"balance_after":44697,"source":{"system":"sec-edgar","filing":"0001415889-24-022424","document":"form4-08282024_040804.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1872285/000141588924022424/form4-08282024_040804.xml","form_type":"4"}},{"id":1421009,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":29785,"kind":"person","name":"Kohler Terry","position":1,"cik":"0001872285","reported_name":"Kohler Terry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-08-28T20:15:08.000Z","date":"2024-08-26","kind":"sale","planned":false,"acquired":false,"shares":21820,"price":2.66,"value":58041.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary sale by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.53 to $2.83 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3)."}],"balance_after":52596,"source":{"system":"sec-edgar","filing":"0001415889-24-022424","document":"form4-08282024_040804.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1872285/000141588924022424/form4-08282024_040804.xml","form_type":"4"}},{"id":1420852,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":83525,"kind":"person","name":"White Ted","position":1,"cik":"0001741964","reported_name":"White Ted","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2024-08-28T20:15:05.000Z","date":"2024-08-27","kind":"sale","planned":false,"acquired":false,"shares":9021,"price":2.46,"value":22191.66,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary sale by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.40 to $2.53 inclusive."}],"balance_after":215967,"source":{"system":"sec-edgar","filing":"0001415889-24-022423","document":"form4-08282024_040801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924022423/form4-08282024_040801.xml","form_type":"4"}},{"id":1420851,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":83525,"kind":"person","name":"White Ted","position":1,"cik":"0001741964","reported_name":"White Ted","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2024-08-28T20:15:05.000Z","date":"2024-08-26","kind":"sale","planned":false,"acquired":false,"shares":24979,"price":2.66,"value":66444.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary sale by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.53 to $2.83 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3)."}],"balance_after":224988,"source":{"system":"sec-edgar","filing":"0001415889-24-022423","document":"form4-08282024_040801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924022423/form4-08282024_040801.xml","form_type":"4"}},{"id":1420961,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":81825,"kind":"person","name":"Hayes Christopher G.","position":1,"cik":"0001805359","reported_name":"Hayes Christopher G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2024-08-28T16:15:14.000Z","date":"2024-08-27","kind":"sale","planned":false,"acquired":false,"shares":9530,"price":2.46,"value":23443.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary sale by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.40 to $2.53 inclusive."}],"balance_after":105773,"source":{"system":"sec-edgar","filing":"0001415889-24-022427","document":"form4-08282024_040809.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805359/000141588924022427/form4-08282024_040809.xml","form_type":"4"}},{"id":1420960,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":81825,"kind":"person","name":"Hayes Christopher G.","position":1,"cik":"0001805359","reported_name":"Hayes Christopher G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2024-08-28T16:15:14.000Z","date":"2024-08-26","kind":"sale","planned":false,"acquired":false,"shares":26183,"price":2.66,"value":69646.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary sale by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.53 to $2.83 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3)."}],"balance_after":115303,"source":{"system":"sec-edgar","filing":"0001415889-24-022427","document":"form4-08282024_040809.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805359/000141588924022427/form4-08282024_040809.xml","form_type":"4"}},{"id":1449922,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":83525,"kind":"person","name":"White Ted","position":1,"cik":"0001741964","reported_name":"White Ted","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2024-07-23T22:13:03.000Z","date":"2024-07-23","kind":"sale","planned":false,"acquired":false,"shares":154,"price":6.98,"value":1074.92,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary sale by the Reporting Person."}],"balance_after":249967,"source":{"system":"sec-edgar","filing":"0001415889-24-019976","document":"form4-07232024_100700.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924019976/form4-07232024_100700.xml","form_type":"4"}},{"id":1449921,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":83525,"kind":"person","name":"White Ted","position":1,"cik":"0001741964","reported_name":"White Ted","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2024-07-23T22:13:03.000Z","date":"2024-07-22","kind":"sale","planned":false,"acquired":false,"shares":32469,"price":7.06,"value":229231.14,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary sale by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.00 to $7.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":250121,"source":{"system":"sec-edgar","filing":"0001415889-24-019976","document":"form4-07232024_100700.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924019976/form4-07232024_100700.xml","form_type":"4"}},{"id":1449920,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":83524,"kind":"person","name":"Bonaccorso Joe","position":1,"cik":"0001741973","reported_name":"Bonaccorso Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF COMMERCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-07-23T22:12:19.000Z","date":"2024-07-23","kind":"sale","planned":false,"acquired":false,"shares":115,"price":6.98,"value":802.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary sale by the Reporting Person."}],"balance_after":106816,"source":{"system":"sec-edgar","filing":"0001415889-24-019974","document":"form4-07232024_100716.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924019974/form4-07232024_100716.xml","form_type":"4"}},{"id":1449919,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":83524,"kind":"person","name":"Bonaccorso Joe","position":1,"cik":"0001741973","reported_name":"Bonaccorso Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF COMMERCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-07-23T22:12:19.000Z","date":"2024-07-22","kind":"sale","planned":false,"acquired":false,"shares":25461,"price":7.06,"value":179754.66,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary sale by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.00 to $7.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":106931,"source":{"system":"sec-edgar","filing":"0001415889-24-019974","document":"form4-07232024_100716.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924019974/form4-07232024_100716.xml","form_type":"4"}},{"id":1449917,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":83526,"kind":"person","name":"Goldenberg Gary","position":1,"cik":"0001741938","reported_name":"Goldenberg Gary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-07-23T22:11:32.000Z","date":"2024-07-23","kind":"sale","planned":false,"acquired":false,"shares":86,"price":6.98,"value":600.28,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary sale by the Reporting Person."}],"balance_after":107750,"source":{"system":"sec-edgar","filing":"0001415889-24-019972","document":"form4-07232024_100729.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924019972/form4-07232024_100729.xml","form_type":"4"}},{"id":1449916,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":83526,"kind":"person","name":"Goldenberg Gary","position":1,"cik":"0001741938","reported_name":"Goldenberg Gary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-07-23T22:11:32.000Z","date":"2024-07-22","kind":"sale","planned":false,"acquired":false,"shares":18421,"price":7.06,"value":130052.26,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary sale by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.00 to $7.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":107836,"source":{"system":"sec-edgar","filing":"0001415889-24-019972","document":"form4-07232024_100729.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924019972/form4-07232024_100729.xml","form_type":"4"}},{"id":1449980,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":81825,"kind":"person","name":"Hayes Christopher G.","position":1,"cik":"0001805359","reported_name":"Hayes Christopher G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2024-07-23T18:10:33.000Z","date":"2024-07-23","kind":"sale","planned":false,"acquired":false,"shares":91,"price":6.98,"value":635.18,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary sale by the Reporting Person."}],"balance_after":141486,"source":{"system":"sec-edgar","filing":"0001415889-24-019970","document":"form4-07232024_100729.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805359/000141588924019970/form4-07232024_100729.xml","form_type":"4"}},{"id":1449979,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":81825,"kind":"person","name":"Hayes Christopher G.","position":1,"cik":"0001805359","reported_name":"Hayes Christopher G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2024-07-23T18:10:33.000Z","date":"2024-07-22","kind":"sale","planned":false,"acquired":false,"shares":21649,"price":7.06,"value":152841.94,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary sale by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.00 to $7.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":141577,"source":{"system":"sec-edgar","filing":"0001415889-24-019970","document":"form4-07232024_100729.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805359/000141588924019970/form4-07232024_100729.xml","form_type":"4"}},{"id":1486752,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":40054,"kind":"person","name":"PRYGOCKI MARK A SR","position":1,"cik":"0001257544","reported_name":"PRYGOCKI MARK A SR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-07T20:15:16.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 6, 2024 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director though the applicable vesting date."}],"balance_after":20000,"derivative":{"exercise_price":8.78,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001415889-24-015961","document":"form4-06072024_040613.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924015961/form4-06072024_040613.xml","form_type":"4"}},{"id":1486751,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":40055,"kind":"person","name":"Eichenfield Lawrence","position":1,"cik":"0001814892","reported_name":"Eichenfield Lawrence","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-07T20:15:16.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 6, 2024 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director though the applicable vesting date."}],"balance_after":20000,"derivative":{"exercise_price":8.78,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001415889-24-015959","document":"form4-06072024_040609.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924015959/form4-06072024_040609.xml","form_type":"4"}},{"id":1487013,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":35681,"kind":"person","name":"Nguyen Diem","position":1,"cik":"0001814338","reported_name":"Nguyen Diem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-07T20:15:14.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 6, 2024 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director though the applicable vesting date."}],"balance_after":20000,"derivative":{"exercise_price":8.78,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001415889-24-015960","document":"form4-06072024_040611.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814338/000141588924015960/form4-06072024_040611.xml","form_type":"4"}},{"id":1486749,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":90154,"kind":"person","name":"Ballaron Craig","position":1,"cik":"0001779433","reported_name":"Ballaron Craig","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-07T20:15:12.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 6, 2024 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director though the applicable vesting date."}],"balance_after":20000,"derivative":{"exercise_price":8.78,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001415889-24-015958","document":"form4-06072024_040607.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924015958/form4-06072024_040607.xml","form_type":"4"}},{"id":1568701,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":83526,"kind":"person","name":"Goldenberg Gary","position":1,"cik":"0001741938","reported_name":"Goldenberg Gary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-19T20:31:07.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the total shares subject to the option shall vest on March 15, 2025 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":80000,"derivative":{"exercise_price":4.8,"expiration_date":"2034-03-15","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001415889-24-008542","document":"form4-03192024_040351.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924008542/form4-03192024_040351.xml","form_type":"4"}},{"id":1568700,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":83526,"kind":"person","name":"Goldenberg Gary","position":1,"cik":"0001741938","reported_name":"Goldenberg Gary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-03-19T20:31:07.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs shall vest in equal annual installments on March 15, 2025, March 15, 2026, March 15, 2027 and March 15, 2028 subject to the Reporting Person's continuous service through each applicable date."}],"balance_after":126257,"source":{"system":"sec-edgar","filing":"0001415889-24-008542","document":"form4-03192024_040351.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924008542/form4-03192024_040351.xml","form_type":"4"}},{"id":1569410,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":29785,"kind":"person","name":"Kohler Terry","position":1,"cik":"0001872285","reported_name":"Kohler Terry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-19T20:31:05.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the total shares subject to the option shall vest on March 15, 2025 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":80000,"derivative":{"exercise_price":4.8,"expiration_date":"2034-03-15","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001415889-24-008541","document":"form4-03192024_040349.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1872285/000141588924008541/form4-03192024_040349.xml","form_type":"4"}},{"id":1569409,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":29785,"kind":"person","name":"Kohler Terry","position":1,"cik":"0001872285","reported_name":"Kohler Terry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-03-19T20:31:05.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs shall vest in equal annual installments on March 15, 2025, March 15, 2026, March 15, 2027 and March 15, 2028 subject to the Reporting Person's continuous service through each applicable date."}],"balance_after":74416,"source":{"system":"sec-edgar","filing":"0001415889-24-008541","document":"form4-03192024_040349.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1872285/000141588924008541/form4-03192024_040349.xml","form_type":"4"}},{"id":1568699,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":83524,"kind":"person","name":"Bonaccorso Joe","position":1,"cik":"0001741973","reported_name":"Bonaccorso Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF COMMERCIAL OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-19T20:31:02.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the total shares subject to the option shall vest on March 15, 2025 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":80000,"derivative":{"exercise_price":4.8,"expiration_date":"2034-03-15","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001415889-24-008539","document":"form4-03192024_040347.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924008539/form4-03192024_040347.xml","form_type":"4"}},{"id":1568698,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":83524,"kind":"person","name":"Bonaccorso Joe","position":1,"cik":"0001741973","reported_name":"Bonaccorso Joe","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF COMMERCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-03-19T20:31:02.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs shall vest in equal annual installments on March 15, 2025, March 15, 2026, March 15, 2027 and March 15, 2028 subject to the Reporting Person's continuous service through each applicable date."}],"balance_after":132392,"source":{"system":"sec-edgar","filing":"0001415889-24-008539","document":"form4-03192024_040347.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924008539/form4-03192024_040347.xml","form_type":"4"}},{"id":1568697,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":83525,"kind":"person","name":"White Ted","position":1,"cik":"0001741964","reported_name":"White Ted","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-19T20:31:00.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the total shares subject to the option shall vest on March 15, 2025 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":225000,"derivative":{"exercise_price":4.8,"expiration_date":"2034-03-15","underlying":"Common Stock","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0001415889-24-008538","document":"form4-03192024_040342.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924008538/form4-03192024_040342.xml","form_type":"4"}},{"id":1568696,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":83525,"kind":"person","name":"White Ted","position":1,"cik":"0001741964","reported_name":"White Ted","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2024-03-19T20:31:00.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":112500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs shall vest in equal annual installments on March 15, 2025, March 15, 2026, March 15, 2027 and March 15, 2028 subject to the Reporting Person's continuous service through each applicable date."}],"balance_after":282590,"source":{"system":"sec-edgar","filing":"0001415889-24-008538","document":"form4-03192024_040342.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1660334/000141588924008538/form4-03192024_040342.xml","form_type":"4"}},{"id":1569075,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":81825,"kind":"person","name":"Hayes Christopher G.","position":1,"cik":"0001805359","reported_name":"Hayes Christopher G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF LEGAL OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-19T16:31:14.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the total shares subject to the option shall vest on March 15, 2025 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":80000,"derivative":{"exercise_price":4.8,"expiration_date":"2034-03-15","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001415889-24-008543","document":"form4-03192024_040300.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805359/000141588924008543/form4-03192024_040300.xml","form_type":"4"}},{"id":1569074,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":81825,"kind":"person","name":"Hayes Christopher G.","position":1,"cik":"0001805359","reported_name":"Hayes Christopher G.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2024-03-19T16:31:14.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs shall vest in equal annual installments on March 15, 2025, March 15, 2026, March 15, 2027 and March 15, 2028 subject to the Reporting Person's continuous service through each applicable date."}],"balance_after":163226,"source":{"system":"sec-edgar","filing":"0001415889-24-008543","document":"form4-03192024_040300.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805359/000141588924008543/form4-03192024_040300.xml","form_type":"4"}},{"id":1698118,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":19219,"kind":"person","name":"PERCEPTIVE ADVISORS LLC","position":1,"cik":"0001224962","reported_name":"PERCEPTIVE ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19221,"kind":"person","name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","position":2,"cik":"0001249675","reported_name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19220,"kind":"person","name":"EDELMAN JOSEPH","position":3,"cik":"0001164426","reported_name":"EDELMAN JOSEPH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-12-29T22:27:30.000Z","date":"2023-12-29","kind":"purchase","planned":false,"acquired":true,"shares":115774,"price":7.24,"value":838203.76,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.02 to $7.32 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number shares purchased at each separate price within such range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the \"Master Fund\").  Perceptive Advisors LLC (the \"Advisor\") serves as the investment manager of the Master Fund.  Joseph Edelman is the managing member of the Advisor.  Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":7099182,"source":{"system":"sec-edgar","filing":"0001062993-23-023292","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1164426/000106299323023292/form4.xml","form_type":"4"}},{"id":1698117,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":19219,"kind":"person","name":"PERCEPTIVE ADVISORS LLC","position":1,"cik":"0001224962","reported_name":"PERCEPTIVE ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19221,"kind":"person","name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","position":2,"cik":"0001249675","reported_name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19220,"kind":"person","name":"EDELMAN JOSEPH","position":3,"cik":"0001164426","reported_name":"EDELMAN JOSEPH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-12-29T22:27:30.000Z","date":"2023-12-28","kind":"purchase","planned":false,"acquired":true,"shares":126116,"price":7.08,"value":892901.28,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.76 to $7.30 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number shares purchased at each separate price within such range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the \"Master Fund\").  Perceptive Advisors LLC (the \"Advisor\") serves as the investment manager of the Master Fund.  Joseph Edelman is the managing member of the Advisor.  Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":6983408,"source":{"system":"sec-edgar","filing":"0001062993-23-023292","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1164426/000106299323023292/form4.xml","form_type":"4"}},{"id":1698116,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":19219,"kind":"person","name":"PERCEPTIVE ADVISORS LLC","position":1,"cik":"0001224962","reported_name":"PERCEPTIVE ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19221,"kind":"person","name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","position":2,"cik":"0001249675","reported_name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19220,"kind":"person","name":"EDELMAN JOSEPH","position":3,"cik":"0001164426","reported_name":"EDELMAN JOSEPH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-12-29T22:27:30.000Z","date":"2023-12-27","kind":"purchase","planned":false,"acquired":true,"shares":79726,"price":7.2,"value":574027.2,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.90 to $7.50 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number shares purchased at each separate price within such range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the \"Master Fund\").  Perceptive Advisors LLC (the \"Advisor\") serves as the investment manager of the Master Fund.  Joseph Edelman is the managing member of the Advisor.  Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":6857292,"source":{"system":"sec-edgar","filing":"0001062993-23-023292","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1164426/000106299323023292/form4.xml","form_type":"4"}},{"id":1700328,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":19219,"kind":"person","name":"PERCEPTIVE ADVISORS LLC","position":1,"cik":"0001224962","reported_name":"PERCEPTIVE ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19221,"kind":"person","name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","position":2,"cik":"0001249675","reported_name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19220,"kind":"person","name":"EDELMAN JOSEPH","position":3,"cik":"0001164426","reported_name":"EDELMAN JOSEPH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-12-27T00:21:16.000Z","date":"2023-12-26","kind":"purchase","planned":false,"acquired":true,"shares":54652,"price":6.49,"value":354691.48,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.395 to $6.50 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number shares purchased at each separate price within such range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the \"Master Fund\").  Perceptive Advisors LLC (the \"Advisor\") serves as the investment manager of the Master Fund.  Joseph Edelman is the managing member of the Advisor.  Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":6777566,"source":{"system":"sec-edgar","filing":"0000899243-23-020691","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1164426/000089924323020691/doc4.xml","form_type":"4"}},{"id":1700327,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":19219,"kind":"person","name":"PERCEPTIVE ADVISORS LLC","position":1,"cik":"0001224962","reported_name":"PERCEPTIVE ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19221,"kind":"person","name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","position":2,"cik":"0001249675","reported_name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19220,"kind":"person","name":"EDELMAN JOSEPH","position":3,"cik":"0001164426","reported_name":"EDELMAN JOSEPH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-12-27T00:21:16.000Z","date":"2023-12-22","kind":"purchase","planned":false,"acquired":true,"shares":250000,"price":6.67,"value":1667500.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.26 to $6.89 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number shares purchased at each separate price within such range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the \"Master Fund\").  Perceptive Advisors LLC (the \"Advisor\") serves as the investment manager of the Master Fund.  Joseph Edelman is the managing member of the Advisor.  Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":6722914,"source":{"system":"sec-edgar","filing":"0000899243-23-020691","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1164426/000089924323020691/doc4.xml","form_type":"4"}}],"next_cursor":"2023-12-27T00:21:16.000000Z,1700327"}